#eli-lilly

Eli Lilly's Experimental Obesity Drug Achieves 23.7% Weight Loss in Late-Stage Trial

Eli Lilly's experimental obesity drug produced an average 23.7% weight loss in a late-stage trial, boosting the stock as investors weigh commercial size, approval timing and outlook.

Eli Lilly’s retatrutide shows strong weight loss and eases knee pain in late-stage trial

Eli Lilly’s retatrutide produced notable weight loss and eased knee pain in a late-stage trial, reinforcing the drugmaker’s obesity strategy alongside Zepbound and an oral candidate.